logo
  

Jacobio Pharma Receives IND Approval In China For Its Therapy On Advanced Colorectal Cancer

Jacobio Pharma said that it has received the Investigational New Drug or the "IND" approval of the combination therapy of KRAS G12C inhibitor JAB-21822 and Cetuximab injection from the Center for Drug Evaluation of China or the "CDE" on December 3, 2021.

Therefore, Jacobio noted that it will start a phase I/II, open-label, multi-center, dose-escalation and expansion clinical trial in China. The clinical trial is aiming to explore the safety, tolerability and preliminary efficacy of the combination therapy of JAB-21822 and Cetuximab in KRAS G12C mutant patients with advanced colorectal cancer.

Jacobio's preclinical study shows that the combination therapy of JAB-21822 and Cetuximab can enhance the anti-tumor activity of JAB-21822 inhibitors in colorectal cancer tumor models, make tumor regression, and delay tumor re-growth after the cessation of using the drug.

JAB-21822 has been approved for five clinical trials in China and the United States, including mono therapies and combination therapies with either PD-1 antibody or Cetuximab to treat KRAS G12C mutant patients with advanced solid tumors including non-small cell lung cancer and colorectal cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cargill, Inc., a privately held food company, is recalling certain chocolate products containing recalled Jif peanut butter due to the potential for salmonella contamination, the U.S. Food and Drug Administration said. The recall involves 795, 8-ounce boxes of Wilbur brand products, such as Milk and Dark Chocolate Covered Peanut Butter Ritz Crackers, Peanut Butter Meltaways... The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals, Inc.'s Dupixent (dupilumab) to treat eosinophilic esophagitis or EoE, a chronic immune disorder. It is the first FDA approval to treat EoE in adults and pediatric patients 12 years and older weighing at least 40 kilograms. Food products maker J. M. Smucker Co. has recalled select Jif peanut butter products sold in the United States due to potential Salmonella contamination, the U.S. Food and Drug Administration said. The recall involves various creamy, crunchy, natural, no added sugar, and reduced fat peanut butter, among others with lot codes 1274425 - 2140425.
Follow RTT